BioNexus Gene Lab Corp. (BGLC)
OTCMKTS: BGLC · Delayed Price · USD
0.514
0.00 (0.02%)
Jul 22, 2024, 9:37 AM EDT - Market open
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $9.78M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $2.38M with 0.20% year-over-year growth. In the year 2023, BioNexus Gene Lab had annual revenue of $9.77M.
Revenue (ttm)
$9.78M
Revenue Growth
-4.88%
P/S Ratio
0.93
Revenue / Employee
$325,848
Employees
30
Market Cap
9.08M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
| Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
| Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
| Dec 31, 2020 | 11.39M | 11.26M | 8,872.03% |
| Dec 31, 2019 | 126.96K | -85.37K | -40.21% |
| Dec 31, 2018 | 212.33K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BHP Group | 55.34B |
| Rio Tinto Group | 54.04B |
| Vale S.A. | 41.78B |
| Linde | 32.76B |
| Freeport-McMoRan | 23.79B |
| The Sherwin-Williams Company | 22.98B |
| Ecolab | 15.50B |
| Newmont | 13.16B |
BGLC News
- 3 months ago - BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - GlobeNewsWire
- 1 year ago - BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market - GlobeNewsWire
- 1 year ago - BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market - GlobeNewsWire